Mercalm

Quick links to important sections

Mercalm

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mercalm

Property Description
Active Ingredients Dimenhydrinate and Caffeine
Form Oral tablets (film-coated, scored)
Pharmacological Class Antihistamine and CNS Stimulant
Common Use Alleviating motion sickness symptoms
Origin Synthetic combination product

Mercalm is a synthetic combination medicine supplied as an oral tablet, primarily classified as an antinaupathic agent designed to combat the adverse effects of motion sickness. This medicine is characterized by its dual action, containing the two distinct active ingredients: Dimenhydrinate and Caffeine. Mercalm is often positioned for travel use, differentiating itself by explicitly offering a balanced approach to the dual problems of motion sickness and drowsiness.

Mercalm belongs to the pharmacological group known as an Antihistamine (H1-type receptor blocker), due to its Dimenhydrinate component, coupled with a Central Nervous System Stimulant provided by the inclusion of Caffeine, a methylxanthine derivative. The antihistamine Dimenhydrinate is used for the prevention and treatment of motion sickness. This medicine is intended to prevent the feeling of sickness associated with travel. This dual composition is a distinctive feature of the Mercalm formulation.

Composition and General Therapeutic Purpose

Mercalm is formulated as a combination product to alleviate symptoms of motion sickness, including nausea, vomiting, and associated dizziness, which arise from travel. The preparation is available in the dosage form of oral tablets, which are typically film-coated and scored. This feature—being scored—is a practical distinction, allowing the tablet to be divided precisely, a useful characteristic when treating different age groups or managing symptoms.

The composition is purposeful: the Dimenhydrinate component works by calming the signals transmitted from the inner ear's balance apparatus to the brain. Crucially, the Caffeine component is included to directly counteract the often-pronounced sedative action associated with the antihistamine. The inclusion of Caffeine is a common practice in combination anti-motion sickness therapies to offset fatigue. This combination is designed to maintain cognitive function during treatment. The stimulant component helps minimize drowsiness while providing anti-sickness relief. By combining these two active ingredients, Mercalm achieves its general therapeutic purpose of enhancing comfort and alertness during movement, such as on long bus journeys or ferry crossings.

Regulatory References

  1. NIH: MedlinePlus - Dimenhydrinate
  2. FDA DailyMed: Dimenhydrinate Labeling

What side effects are possible with Mercalm?

Possible Side Effects and Safety Information

The safety profile of Mercalm is defined by the officially documented effects of its active components, Dimenhydrinate (an antihistamine) and Caffeine (a CNS stimulant). This section describes the types and frequency of adverse reactions as classified in government regulatory documents.


Frequency and System-Organ Classification

The most frequently reported adverse reaction is Drowsiness (Sedation), which is classified as Common in official labeling. Effects are primarily observed across the Nervous System and systems governed by anticholinergic action. The less common, or unquantified, effects listed in regulatory documents include dizziness, headache, dry mouth (xerostomia), and blurred vision.

System-organ classes involved include the Gastrointestinal system (e.g., anorexia, constipation), the Renal and Urinary system (e.g., urinary retention, difficult urination), and Cardiac disorders (e.g., palpitation, tachycardia), which may be influenced by the stimulant component.


Serious Adverse Reactions and Population Notes

While generally rare, regulatory documents note the occurrence of serious adverse reactions, including convulsions/seizures, and severe hypersensitivity reactions (such as anaphylaxis). Use is generally contraindicated in specific pre-existing conditions, notably narrow-angle glaucoma and prostatic hypertrophy due to the risk of exacerbating urinary retention.

Official labels contain specific safety considerations for certain groups: Older adults are more sensitive to adverse effects, particularly sedation and urinary retention. Children may experience paradoxical CNS stimulation, manifesting as excitement or restlessness. The sedative effect may diminish after a few days of treatment.

Overdose and Emergency Response

Mercalm Overdose and when to seek help

This information describes the documented profile of overdose as stated in government regulatory sources for products containing Dimenhydrinate and Caffeine.

Overdose Scope

Property Documented Regulatory Description
Documented overdose presentations Symptoms may include signs of anticholinergic toxicity and CNS stimulation, such as mydriasis (dilated pupils), flushing, dry mouth, hallucinations, ataxia, tremors, agitation, drowsiness (somnolence), or vomiting (MedlinePlus, FDA).
Physiological systems affected Central Nervous System (CNS), Cardiovascular System, and Metabolic System.
Dose-related or exposure-related factors Overdose risk is associated with excessive ingestion and may be worsened by the concurrent use of other CNS depressants, as described in regulatory documents.
Population-specific overdose notes Children may exhibit increased severity, including paradoxical CNS excitation and seizures; the elderly are more susceptible to severe anticholinergic effects.
Emergency-response statements Management involves primarily symptomatic and supportive treatment. No specific antidote is known for the Dimenhydrinate component. Treatment may include activated charcoal, gastric lavage, and administering benzodiazepines for agitation or seizures.
When immediate medical help is required Seek immediate medical attention or contact emergency services immediately upon any suspicion of overdose. Urgent care is necessary for severe outcomes, including cardiac arrhythmias, profound CNS depression (coma), or seizures.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to severe and life-threatening outcomes, including serious arrhythmias and cardio-respiratory arrest.
  • Continuous hospital monitoring and cardio-respiratory monitoring is a required component of patient management, alongside checking electrolyte levels and renal function.

Connection to the overall overdose profile: Regulatory documents define the overdose profile based on the dual risk of CNS depression and severe cardiac or neurological toxicity. This requires healthcare providers to prioritize immediate intervention and supportive measures in a monitored hospital setting, consistent with the documented lack of a specific reversal agent.

Therapeutic Uses of Mercalm

What Mercalm Treats: Main Uses and Benefits

Mercalm is applied across therapeutic domains involving episodic symptom patterns where short-term supportive relief is required. It is relevant for addressing symptoms in conditions marked by disruptive manifestations, and generally contributes to improved comfort and stability when symptoms become noticeable. Its core component is commonly used to help with the prevention and treatment of symptoms associated with motion sickness.


The medication is used for managing the acute symptoms of motion sickness, including nausea, vomiting, and dizziness or vertigo. It is commonly used when symptoms intensify, such as during sea, air, or long-distance land travel. The formulation addresses two symptom areas: it is applied in contexts where supportive management is required for travel sickness, while also helping to manage the common sedative action that may interfere with alertness.

“It may assist with maintaining functional stability and supports the patient by easing distress related to fatigue.”

Quick Fact: Relief for Vestibular Discomfort The formulation supports symptom management in situations involving symptoms related to systemic imbalance (vestibular system), while also helping manage symptoms that interfere with daily functioning (drowsiness).

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Mercalm?

Regulatory documents define population eligibility for Mercalm (Dimenhydrinate and Caffeine) by listing specific contraindications and age restrictions. The medicine is contraindicated in children under 6 years of age. Use is also strictly prohibited for individuals with narrow-angle glaucoma or conditions that increase the risk of urinary retention, such as prostatic hypertrophy.

Condition-Based Restrictions

Population Group Eligibility Status
Children lt 6 years Contraindicated
Glaucoma/Urinary Retention Risk Contraindicated
Pregnancy/Lactation Not Recommended
Hepatic/Renal Impairment Use with Caution (Requires adjustment)
Older Adults Use with Caution (Requires medical advice)

Standard labeled use is approved for adults and adolescents 15 years and older, and children from 6 to 15 years. Use is not recommended during pregnancy or breastfeeding. Furthermore, patients with pre-existing conditions like liver or kidney disease, asthma, or certain cardiac arrhythmias must exercise caution and may require dosage adjustments, as these conditions affect drug clearance or may be aggravated by its components.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mercalm’s interaction profile is based on the documented effects of its dual active ingredients, Dimenhydrinate (an antihistamine) and Caffeine (a CNS stimulant). Regulatory documents classify interactions based on additive pharmacodynamic effects and pharmacokinetic pathway interference.

Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) Depressants, such as opioids, sedatives, and hypnotics, causes an official potentiation of effects, leading to increased sedation. The drug also intensifies the effects of Anticholinergic Drugs and Monoamine Oxidase Inhibitors (MAOIs), prolonging anticholinergic effects. Conversely, combining Mercalm with other CNS Stimulants results in additive effects, which may increase the risk of adverse cardiovascular events. Co-consumption with Alcohol (Ethanol) is formally advised against due to documented increased CNS depressant effects.

Pharmacokinetic and Exposure Interactions

The Dimenhydrinate component acts as an inhibitor of the CYP2D6 enzyme, which suggests a potential for interaction with medicines primarily metabolized by this pathway. The Caffeine component is a substrate of CYP1A2, meaning inhibitors of this enzyme may reduce caffeine clearance and increase exposure. Furthermore, the drug has a documented interaction with Lithium, where the Caffeine component may increase the renal clearance of Lithium, potentially altering its therapeutic concentration.

Mechanism of Action

The action of this combination drug is rooted in two distinct Central Nervous System (CNS) mechanisms that work together to modulate specific neural pathways.

Vestibular Signal Attenuation via Receptor Blockade

The anti-sickness mechanism involves the competitive blockade of H1 Histamine receptors and Muscarinic Acetylcholine receptors in the brainstem, particularly within the vestibular nuclei and Chemoreceptor Trigger Zone (CTZ). By occupying these sites, the drug prevents the excitatory signals—transmitted from the inner ear's balance apparatus—from activating these critical centers, thereby dampening the emetic reflex pathway. This action results in the reduction of signal flow from the vestibular system to the emetic centers.

CNS Arousal Modulation through Adenosine Antagonism

The secondary mechanism involves Caffeine acting as an antagonist of Adenosine receptors ( A1 and A2 A) in the CNS. Since endogenous adenosine typically acts to suppress neuronal activity, blocking it removes this natural inhibitory influence. This effectively opposes the inherent CNS depression caused by the H1 antihistamine component. This functional pharmacodynamic offset results in the counter-modulation of the CNS arousal system, counteracting the reduced neuronal activity associated with the antihistamine component.

Dosage and Administration Information

Official Administration Principles

Mercalm is formulated as an oral tablet and is used as an as-needed regimen for motion-related symptoms. The medication is administered via the oral route, swallowed with a small amount of water.

For prophylaxis—that is, for preventing symptoms before they occur—the initial dose is taken approximately 30 minutes prior to the start of the activity or travel. Subsequent doses, if required, must adhere to the specific time constraints established for the medicine.


Standard Labeled Dosing Regimen

Dosing instructions specify distinct maximums and frequencies for adult and pediatric populations. The regimen includes a specific maximum daily limit and dosing interval for this combination product.

Population Single Dose Range (Dimenhydrinate equivalent) Maximum Daily Dose (24h) Minimum Dosing Interval
Adults and Children 15 and older 50 mg to 100 mg (1 to 2 tablets) 300 mg (6 tablets) 6 hours
Children 6 to 15 years 25 mg to 50 mg (0.5 to 1 tablet) 150 mg (3 tablets) 6 hours

Use Context and Frequency

Administration is limited to a maximum of three doses per day and is intended for episodic relief. The tablet is designed to be scored, facilitating the accurate measurement of half-doses for the pediatric regimen. Due to its specific composition, the medication is restricted to patients who are 6 years of age and older.

Recent Clinical Evidence

Research Evidence Supporting Mercalm's Use

This section summarizes the official research evidence, including randomized controlled trials and scientific reviews, that regulators rely upon for the medicine's core purpose. Studies help show what has been observed so far, providing context about group patterns but not individual predictions.


Evidence for Use in Managing Motion Sickness Symptoms

The anti-nausea component of Mercalm was evaluated in research exploring symptoms of motion sickness, such as nausea, vomiting, and dizziness. Researchers primarily used Randomized Controlled Trials (RCTs) and experimental studies where participants was observed in motion simulators or other controlled settings designed to bring on temporary physiological imbalance. The main study outcomes that research examined included patient-reported outcomes describing perceived discomfort, specifically related to physical discomfort like nausea severity and the frequency of vomiting.

These studies report how symptoms evolved in the observed populations. Some trials described patterns where the anti-nausea component showed measured differences in nausea, vomiting, and dizziness scores compared to placebo. However, findings were sometimes mixed across studies, and many of these clinical evaluations results apply only to the populations studied—primarily healthy adults—under the specific, short-term conditions in which they was conducted.


Research on Alertness and Counteracting Sedation

Research explored scenarios involving the anti-nausea ingredient and a Central Nervous System stimulant like caffeine, as the anti-nausea component was associated with drowsiness in some studies. Randomized Controlled Trials were a key study design, where participants were evaluated using vigilance tasks and psychomotor performance testing. These studies specifically monitored outcomes reflecting daily functioning or activity level, such as reaction time and accuracy on focused tasks.

The studies reported measurements of specific performance metrics, such as speed and error rates in these functional tasks, when the two components were used together compared to the anti-nausea component alone. These findings help contextualize patterns observed when the stimulant component was included. However, the evidence is not fully established regarding real-world tasks, as the studies often used simulated, single-task environments.


What Research Gaps and Uncertainty Remain

Research has focused mainly on short-term or episodic symptom patterns relevant for acute travel situations. Consequently, follow-up durations were limited in most key studies. Data describing long-term outcomes are not well characterized. The sample sizes were modest in many older trials, and evidence quality varies across studies.

Data for certain groups remain insufficient. For instance, there is limited information about the specific Mercalm combination product in older adults or people with complex comorbid conditions. The lack of large-scale, published comparative evidence directly pitting the specific Mercalm combination product against all other popular motion sickness preventatives also represents a gap in the evidence landscape.

Key Studies & References

  1. Dimenhydrinate (General Overview: Used to confirm core indication)

Frequently Asked Questions (FAQ)

Common questions about Mercalm (FAQ)

Q: Is Mercalm the same type of medicine as [similar drug name]?

Mercalm is a combination medicine containing Dimenhydrinate, which belongs to the class of first-generation antihistamines used to prevent motion sickness. This pharmacological class includes other medications like meclizine or scopolamine, which are also used for the same purpose.

Q: How quickly does Mercalm start working after I take it?

According to official administration principles, the first dose is typically recommended to be taken 30 to 60 minutes before the start of motion for prevention. This timeframe is advised because the anti-sickness effects of the medicine are expected to begin shortly after administration.

Q: What happens if I stop taking Mercalm suddenly?

When Mercalm is taken as directed for short periods (episodic use), suddenly stopping is generally not associated with severe withdrawal. However, regulatory warnings exist about the potential for symptoms like headaches, restlessness, or rebound nausea if heavy, prolonged use or misuse is suddenly discontinued.

Q: Do I need a special prescription from a specialist for Mercalm?

The active ingredients in Mercalm, Dimenhydrinate and Caffeine, are widely available as over-the-counter (OTC) medications. Therefore, Mercalm does not require a prescription.

Q: Is Mercalm considered a narcotic or controlled substance?

Mercalm is classified as an antihistamine and a central nervous system stimulant. Official sources confirm that this medicine is not listed as a narcotic or a federally controlled substance.

Q: How long does Mercalm stay in your system?

The most relevant information from regulatory documents is the duration of its anti-nausea effect. This effect is generally expected to last approximately four to six hours, which aligns with the recommended minimum dosing interval.

Q: Can Mercalm be taken with pain relievers like ibuprofen?

Regulatory interaction checkers and product information generally do not list a specific, major interaction between the active ingredients in Mercalm and common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. General guidance emphasizes the importance of discussing the use of any medication, including OTC drugs, with a healthcare professional.

Q: Are there any known long-term side effects associated with Mercalm?

Most studies on Mercalm have focused on short-term, episodic use, meaning long-term data is limited. Regulatory warnings advise that prolonged exposure to the antihistamine component has been linked to potential memory and focus issues, particularly with high-dose or older adult use.

Q: Can Mercalm interact with herbal supplements like St. John's Wort?

Official guidance notes the importance of informing a healthcare provider about all medicines and supplements being taken. This general instruction includes herbal products and supplements, as they may interact with the medicine's active ingredients.

Q: Is there a generic version of Mercalm available?

The individual active ingredients in Mercalm—Dimenhydrinate and Caffeine—are widely available as generic and branded products globally. Mercalm itself is a specific combination formulation.

Q: Are there any specific foods or drinks I should avoid while taking Mercalm?

Regulatory information formally advises against consuming alcohol due to the increased risk of sedation. Official recommendations for managing motion sickness often involve avoiding heavy meals, strong odors, spicy, and greasy foods while traveling.

Q: Do studies show Mercalm is more or less studied than older medicines for the same condition?

The Dimenhydrinate component has been widely studied for motion sickness prevention. However, regulatory documentation highlights a research gap regarding large-scale published studies that directly compare the specific Mercalm combination product against all other popular motion sickness preventatives.

Q: Does Mercalm interact with common blood pressure medications?

Due to the potential for the antihistamine component to cause infrequent cardiovascular effects, including hypertension (high blood pressure), and the stimulant component's effect on heart rate, regulatory documents contain a cautionary note regarding use by individuals with pre-existing cardiovascular conditions.

Q: What is the risk of dependence or addiction with Mercalm?

While Mercalm is not a controlled substance, regulatory warnings and safety resources note a potential for misuse, physical or psychological dependence, and addiction-like behavior. This risk is primarily associated with prolonged periods of use or when taken at high doses outside of the recommended guidelines.

Q: What does 'contraindication' mean in relation to Mercalm?

A contraindication refers to a specific condition or circumstance where the use of a particular drug, like Mercalm, would be harmful to the patient. For Mercalm, contraindications include conditions like narrow-angle glaucoma or conditions that increase the risk of urinary retention.

Q: Do official sources list caffeine as an interaction with Mercalm?

Since Mercalm already contains a central nervous system stimulant (Caffeine), official product information contains a warning about the consumption of additional caffeine-containing products due to the risk of increased side effects such as nervousness, irritability, and rapid heart rate.

Q: What is the difference between Mercalm and over-the-counter sleep aids?

Mercalm is a unique combination product designed specifically to treat motion sickness. The stimulant component (Caffeine) is included to help counteract the drowsiness typically caused by the antihistamine, which differentiates it from most simple over-the-counter sleep aids that rely only on the sedating effect.

Q: What is the expected duration of effect from a single dose of Mercalm?

The duration of the anti-nausea and anti-vomiting effect is typically expected to be approximately four hours per dose.

Q: Can Mercalm cause changes in mood or behavior?

Official labeling lists changes such as nervousness, restlessness, and insomnia as potential side effects. Regulatory notes specifically point out that children may experience paradoxical central nervous system (CNS) stimulation, which can manifest as excitement or restlessness.

Q: Can men and women use Mercalm for the same conditions?

Regulatory documents, including the official label, do not differentiate the use or indications of Mercalm for motion sickness between men and women.

Q: Does Mercalm need to be taken at a specific time of day?

Mercalm is intended for use as an as-needed regimen, specifically tied to travel or activity. It is not required to be taken at a fixed time of day, but rather approximately 30 minutes before exposure to motion.

Q: Does Mercalm interact with oral contraceptives?

The estrogen component of some oral contraceptives can increase the concentration of the Caffeine component in the blood. This pharmacokinetic interaction may increase the risk of caffeine-related side effects. Official documents highlight this potential interaction, suggesting that monitoring by a healthcare provider may be required.

Q: Why do people confuse Mercalm with an anxiety medication?

Mercalm contains an antihistamine component that provides a sedating or calming effect on the central nervous system. This known sedative property has, in some contexts, led individuals to misuse it or confuse it with medications intended to treat anxiety.

Q: What are the typical side effects that resolve quickly when taking Mercalm?

Regulatory documents specifically note that the sedative effect, which is the most common side effect, may diminish after a few days of continuous treatment.

Q: What kind of monitoring might be required while using Mercalm?

Regulatory information notes that Mercalm should be used with caution in high-risk individuals, such as those with kidney, liver, or heart disease. In such cases, the treating physician determines the appropriate level of monitoring for cardiovascular and overall health status.

Q: Do regulatory bodies classify Mercalm as having high or low potential for misuse?

Regulatory and safety resources caution that the Dimenhydrinate component of Mercalm has a documented potential for misuse and abuse. This risk is primarily noted among young adults, despite the drug’s over-the-counter availability.

Q: Is Mercalm mentioned in any major national treatment guidelines?

The Dimenhydrinate component of Mercalm is a first-generation antihistamine that is widely included in resources detailing over-the-counter options for motion sickness prevention in major clinical and patient resources.

Q: Does the effectiveness of Mercalm change over time?

Tolerance, or the need for increased amounts to achieve the same effect, may develop with prolonged or excessive use. Additionally, official labeling notes that the sedating effect of the antihistamine component may diminish after a few days of continuous treatment.

Q: Does the effectiveness of Mercalm change over time?

Tolerance, or the need for increased amounts to achieve the same effect, may develop with prolonged or excessive use. Additionally, official labeling notes that the sedating effect of the antihistamine component may diminish after a few days of continuous treatment.

Q: Does Mercalm interact with herbal calming teas like chamomile?

Official guidance notes the importance of informing a healthcare provider about all medicines and supplements being taken, which includes herbal products and teas, as they may interact with the drug's active ingredients.

Q: Can I use Mercalm if I already take a vitamin D supplement?

Official guidance notes the importance of informing a healthcare provider about all other products being used, including vitamins and supplements, to avoid potential interactions with Mercalm's components.

How should Mercalm be stored and disposed of?

Storage and Disposal of Mercalm (Dimenhydrinate and Caffeine)

Mercalm oral tablets must be stored according to official regulatory specifications to maintain product integrity and safety.

Storage Requirements

The medication requires storage at controlled room temperature, generally defined as 15 C to 30 C (59 F to 86 F). The product must be protected from freezing, excess heat, and moisture. Store the tablets in the container in which they were originally dispensed, ensuring the container remains tightly closed to avoid degradation. The product must be kept out of the sight and reach of children in a secure location.

Disposal Instructions

Unused or expired Mercalm should be disposed of through a medicine take-back program. If a take-back option is unavailable, the product must be mixed with an undesirable substance (e.g., dirt) and sealed in a container before discarding it in the household trash. Mercalm is not on the list of medicines recommended for disposal by flushing down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mercalm found in:

A-Z Index: